(NASDAQ: IVVD) Invivyd's forecast annual revenue growth rate of 55.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Invivyd's revenue in 2026 is $55,866,000.On average, 5 Wall Street analysts forecast IVVD's revenue for 2026 to be $25,492,382,822, with the lowest IVVD revenue forecast at $21,047,345,586, and the highest IVVD revenue forecast at $30,005,768,986. On average, 5 Wall Street analysts forecast IVVD's revenue for 2027 to be $28,136,779,311, with the lowest IVVD revenue forecast at $15,301,911,057, and the highest IVVD revenue forecast at $35,482,521,519.
In 2028, IVVD is forecast to generate $62,023,706,870 in revenue, with the lowest revenue forecast at $37,647,886,291 and the highest revenue forecast at $96,451,533,710.